An AI powered supertest for prostate cancer is being hailed as the most accurate tool yet in detecting the disease. It offers hope for earlier diagnosis and more personalized treatment for patients.
In the UK there is no routine screening for prostate cancer. This is because currently testing methods are considered unreliable.
Identifies 100 Biomarkers
The AI supertest analyses blood and samples by assessing and identifying over 100 biomarkers that have been clinically validated as having a connection to prostate cancer. Current leading tests only work on 20 biomarkers per test.
The new AI powered test will give a comprehensive health overview in relation to prostate cancer. This includes assessing not only if the disease is present and what stage it is but also the overall risk of developing prostate cancer in the future.
Read: CHIEF AI Can Detect Multiple Forms of Cancer
EDX Medical Group, the company behind the test's development, hope to launch the test privately across the UK over the next year.
The company have filed a patent application for both the test and AI algorithm behind it. During this time the scientific team are working to validate further clinical data. Their next steps will be so seek regulatory approval from the Medicines & Healthcare Products Regulatory Agency (MHRA) and the US Food and Drug Administration (FDA) .
99% Accuracy
The AI algorithm behind the test highlights early signs of cancer and works to guide the ongoing treatment. The test is also able to identify different subtypes of prostate cancer.
Read: What is Health Technology? Definition, Benefits, Challenges
EDX Medical expects the test to achieve high accuracy, with sensitivity and specificity levels between 96-99% across all ages and ethnic groups. This would be a significant improvement over current testing methods, which can have accuracy rates below 50%.
